Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EARLY-HEP-C: Grazoprevir/Elbasvir in HIV/HCV Co-infected Patients
NCT02897596Phase 3Unknown
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Apr 2017
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of grazoprevir and elbasvir in hepatitis C (HCV) (2 arms), sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoint: Sustained virological response at 24 weeks. Status: unknown.
02
Drugs
grazoprevirelbasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02897596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02897596.